Study Conducting By ICMR To Scrutinize The Virtue Of Covishield And Covaxin In Preventing Covid-19

Since the innovation of AstraZeneca’s Covishield and Bharat Biotech’s Covaxin in the country, the Indian Council of Medical Research (ICMR) will appraise a  study  from next week to scrutinize the potency of these vaccines in preclude the concatenation of  Covid into a critical form.

As reported by senior scientist Dr Tarun Bhatnagar  at ICMR’s National Institute of Epidemiology (NIE) in Chennai revealed that, approaching 4,000 folks  the people exceeds  the age of 45 years who have taken each of  two doses either of  two vaccines will be criticized.

“As a part of the study we will take people who are COVID-19 positive and hospitalised and compare their vaccination status with those who have tested Covid negative,” Bhatnagar told PTI. The aim is to assess how effective vaccination is in preventing progression of the disease into a severe form,” he said.

Up to the present time around 20 crore  amassed vaccine doses has disbursed  in the country  so far.

The Central Government is impelling people to get vaccinated by perpetuating that the vaccine will not fortify one from dwindle the corona virus infection but by inoculating the two doses of the vaccine it will prohibits the concatenation to a extreme stage and will bring down the fatality rate.

The central authorities has been pressurizing about the necessity of wearing a face mask and adhesion to covid protocols.

At present India is using 3 vaccines against this pandemic, which includes Covishield, Covaxin , and Sputnik. Among this covishield is  manufactured by the Pune-based Serum Institute and Covaxin of Bharat Biotech in Hyderabad. Finally the Russian Sputnik V needs the approval from Drug Controller General of India (DCGI) for Emergency Use Authorization and is hardly used in private hospitals so far.

This first of its kind study is expected to be undertaken from next week, said Dr Tarun Bhatnagar, senior ICMR scientist.